Cambridge Antibody Technology (CATGY) Inactive
Filed: 9 Jun 06, 12:00am
Exhibit 99.(a)(13)
Excerpts from David Brennan’s presentation to analysts on June 8, 2006:
| Strengthening the pipeline Improve the productivity of AstraZeneca Discovery and Development Acquire externally sourced products and science Build on the CAT acquisition to establish a major international presence in biological therapeutics |
Excerpts from John Patterson’s presentation transcript:
Slide 1
| AZD6244 (ARRY-142886) Solid tumours AZD2479 Dyslipidemia AZD2281 KU59436 Breast cancer AZD1689 (AQ4N) Solid tumours CytoFab(tm) Severe sepsis AZD5896 (Patrin(tm)) Solid tumours AZD3480 Cognitive disorders / Alzheimers AZD5904 MS AZD2327 Anxiety & depression Phase I & II Pipeline CV / GI Respiratory / Inflammation Neuroscience Oncology / Infection AZD9056 Inflammatory bowel disease AZD0837 Thrombosis AZD7009 Atrial fibrillation (IV) AZD9684 Thrombosis AZD3355 GERD AZD8677 Dyslipidemia / Diabetes AZD9272 GERD AZD6610 Dyslipidemia / Diabetes AZD0530 Solid tumours AZD1152 Solid tumours AZD4769 Solid tumours ZD4054 Prostate cancer Zactima(tm) Medullary thyroid cancer AZD9272 Neuropathic pain / anxiety AZD1080 Alzheimer's AZD8955 Osteoarthritis AZD9056 Rheumatoid arthritis AZD9056 COPD AZD8309 Rheumatoid arthritis AZD8309 COPD AZD3342 COPD AZD1981 Asthma AZD5672 Rheumatoid arthritis AZD5904 COPD I II I II I II I II AZD2479 Dyslipidemia AZD6244 (ARRY-142886) Solid tumours AZD2281 KU59436 Breast cancer AZD1689 (AQ4N) Solid tumours CytoFab(tm) Severe sepsis AZD5896 (Patrin(tm)) Solid tumours AZD3480 Cognitive disorders / Alzheimers AZD5904 MS AZD2327 Anxiety & depression Acquired |
Slide 2
| Licensing 2005: AGI-1067 AtheroGenics AZD3480 Targacept CytoFab(tm) Protherics Acquisition: AZD2281, Patrin(tm), AQ4N KuDOS CAT-354, CAT-3888 and CAT-8015 Cambridge Antibody Technology 2006: Abraxane(tm) Abraxis BioScience AZD3043 Theravance |
| Biomarkers and imaging |
Slide 4
| & Building global biologicals capability Build on successful alliance Build a world class capability centred around CAT Invest in next generation of biological medicines AZ global sales and marketing reach AstraZeneca Major Pharma leader with global research and commercial capabilities Resource to transform CAT into a major biological therapeutic player Cambridge Antibody Technology Leading UK-based Biotech company with a strong research platform to deliver innovative biological therapeutics Enhanced biologicals capability to deliver a stronger flow of new medicines to patients |
Slide 5
| Biologicals pilot facility : |
Slide 6
| Biologicals strategy Likely outputs from Abgenix Likely outputs from CAT Attrition rate vs small molecules + + 1/4 Biologicals in late phase II by 2010 = Likely outputs from others + Speed through pre-clinical development + |
Excerpts from Jon Symonds’ presentation to analysts on June 8, 2006:
| Externalisation...what's our thinking US Biologicals Early Portfolio Balance Sheet ? KuDOS ? Protherics ? Targacept ? Abraxis Bioscience CAT ? ? AtheroGenics $50m $210m $41m $10m $200m $1,200m Theravance ? $1m |
Excerpts from Rodger McMillian’s presentation to analysis on June 8, 2006:
Slide 1
| Opportunities in respiratory and inflammation Symbicort(tm) New asthma data COPD update Promising early portfolio Focus on COPD CAT alliance Already benefiting Discovery portfolio |
Slide 2
| Beyond respiratory Mature products Entirely respiratory Inhaled products In house products Small molecules Early stage pipeline Respiratory and rheumatology Oral, inhaled and parenterals In house and partnerships Small molecules and biologicals |
Slide 3
| Background to alliance with Cambridge Antibody Technology Current 5 year alliance initiated December 2004 Focus on respiratory and inflammation 5 new discovery projects per year 2 antibody candidate drugs per year from 2007 Opportunities in other disease area Proprietary technologies Phage Display and Ribosome Display "Human immune system" in a test tube Leader in human monoclonal antibodies as therapeutics CAT Discovery: |
Slide 4
| Target Evaluation Lead Isolation Lead Optimisation Target Validation A B C D E A' Pharmacology and Manufacturing Process Development Milestones Other Res. Areas Other R&I COPD Refractory Asthma OA RA Pre-project Oth1 CAT Alliance Project portfolio Jan 2005 |
Slide 5
| March 2006 CAT Alliance Project portfolio Target Evaluation Lead Isolation Lead Optimisation Target Validation A B C D E A' Pharmacology and Manufacturing Process Development Milestones Other Res. Areas Other R&I COPD Refractory Asthma OA RA Pre-project As2 Oth1 RA1 RA2 RA3 RA4 As1 As3 June 2005 |
Slide 6
| March 2006 CAT Alliance Project portfolio Target Evaluation Lead Isolation Lead Optimisation Target Validation A B C D E A' Pharmacology and Manufacturing Process Development Milestones Other Res. Areas Other R&I COPD Refractory Asthma OA RA Pre-project As2 Oth1 RA1 RA2 RA3 RA4 As1 As3 As4 Co1 OA1 OA3 OA2 |
Slide 7
| Progress report on alliance with Cambridge Antibody Technology Portfolio goals met or exceeded in 2005 Expansion of project portfolio agreed in 3Q 2005 Portfolio now includes projects in Oncology and Neuroscience On track to meet or exceed delivery targets Projects on track for delivery of at least 2 CDs in 2007 Potential for delivery of first CD in 2006 Unique alliance culture: "jointness" True partnership Respect for both partners' distinct strengths A great start! |
Slide 8
| Opportunities in respiratory and inflammation Symbicort(tm) new asthma data COPD update Promising early portfolio focus on COPD CAT alliance already benefiting Discovery portfolio |